Scott N Pinchot
Overview
Explore the profile of Scott N Pinchot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinchot S, Chen H
Expert Rev Endocrinol Metab
. 2019 Feb;
4(6):553-563.
PMID: 30780795
The spectrum of classical primary hyperparathyroidism (pHPT) has expanded from a disabling disease to a largely asymptomatic one, leading to considerable uncertainty regarding which patients with pHPT will truly benefit...
2.
Ricciardi R, Roberts P, Hall J, Read T, Francone T, Pinchot S, et al.
J Gastrointest Surg
. 2014 Jan;
18(4):789-95.
PMID: 24408182
Introduction: The aim of our study was to evaluate the effect of stoma creation on deep and superficial surgical site infections after an index colorectal surgical procedure. Methods: We designed...
3.
Shaverdian N, Pinchot S, Zarebczan B, Gillis H, Schiro A, Chen H
Ann Surg Oncol
. 2012 Sep;
20(2):640-5.
PMID: 22941169
Background: Neuroendocrine (NE) tumors pose a diagnostic challenge with the need to utilize a combination of biochemical analysis, standard cross-sectional imaging, and more recently, nuclear medicine scans such as (111)indium-pentetreotide...
4.
Pinchot S, Youngwirth L, Rajamanickam V, Schaefer S, Sippel R, Chen H
Oncologist
. 2012 Jul;
17(10):1271-6.
PMID: 22829568
Objective: To prospectively evaluate the impact of parathyroidectomy on swallowing-related quality of life using the Swallowing Quality Of Life (SWAL-QOL) validated outcomes assessment tool. Background: Many patients with primary hyperparathyroidism...
5.
Alhefdhi A, Pinchot S, Davis R, Sippel R, Chen H
World J Surg
. 2011 Jun;
35(9):2006-9.
PMID: 21713573
Background: Intraoperative parathyroid hormone (IoPTH) testing is useful in the management of hyperparathyroidism. The successful removal of hypersecreting parathyroids is indicated by a decrease in PTH levels >50% within 15...
6.
Pinchot S, Jaskula-Sztul R, Ning L, Peters N, Cook M, Kunnimalaiyaan M, et al.
Cancer
. 2011 Mar;
117(7):1386-98.
PMID: 21425138
Background: Carcinoids are neuroendocrine (NE) tumors with limited treatment options. Notch activation has been shown to suppress growth and hormone production in carcinoid cells. Methods: The purpose of this study...
7.
Zarebczan B, Pinchot S, Kunnimalaiyaan M, Chen H
Am J Surg
. 2011 Mar;
201(3):329-32.
PMID: 21367373
Background: The investigators' laboratory has demonstrated that the Notch1 signaling pathway acts as a tumor suppressor in carcinoid tumors. The aim of this study was to examine hesperetin, a flavonoid,...
8.
Truong M, Cook M, Pinchot S, Kunnimalaiyaan M, Chen H
Ann Surg Oncol
. 2010 Dec;
18(5):1506-11.
PMID: 21184191
Background: Currently, complete surgical resection is the only curative option for medullary thyroid cancer (MTC). Previous work has shown the Notch pathway is a potent tumor suppressor in MTC and...
9.
Cook M, Pinchot S, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H
Mol Cancer Ther
. 2010 Jan;
9(2):429-37.
PMID: 20103603
Carcinoids are neuroendocrine tumors (NET) that secrete hormones, including serotonin, resulting in the malignant carcinoid syndrome. In addition to the significant morbidity associated with the syndrome, carcinoids are frequently metastatic...
10.
Pinchot S, Kunnimalaiyaan M, Sippel R, Chen H
J Oncol
. 2010 Jan;
2009:183031.
PMID: 20069043
Medullary thyroid cancer (MTC) is a rare neuroendocrine neoplasm that accounts for approximately 5% of all thyroid malignancies. The natural history of MTC is characterized by early lymph node and...